Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

NCT00805376 is registered in ClinicalTrials.gov with DNAtrix, Inc. as lead sponsor.

NCT NCT00805376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00805376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Lead sponsor
DNAtrix, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2009
Completion date
February 28, 2015
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, central nervous system diseases